Navigation Links
Vasogen to Present at the BIO CEO & Investor Conference and Participate on the Non-Cancer Immunotherapy Panel
Date:2/5/2008

so developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead candidate from this new class of drugs.

Certain statements contained in this press release, the upcoming webcast, or elsewhere in our public documents constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and/or "forward-looking information" under the Securities Act (Ontario). These statements may include, without limitation, plans to advance the development of Celacade(TM) or VP025, plans to fund our current activities, statements concerning our partnering activities, health regulatory submissions, strategy, future operations, future financial position, future revenues and projected costs. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expects", "plans", "anticipates", "believes", "estimated", "predicts", "potential", "continue", "intends", "could", or the negative of such terms or other comparable terminology. We made a number of assumptions in the preparation of these forward-looking statements, including assumptions about the nature, size, and accessibility of the market for Celacade in the treatment of chronic heart failure, particularly in Europe, the regulatory approval process leading to commercialization and the availability of capital on acceptable terms to pursue the development of Celacade, and the feasibility of additional trials. You should not place undue reliance on our forward-looking statements which are subject to a multitude of risks and uncertainties that could cause actual results, future circumstances or events to differ materially from those projected. These risks include, but are not limited to, the outcome of further ongoing analysis of the ACCLAIM trial results, the requirement or election to conduct additional clinical trials and the size and design of any such trials, delays or setbacks
'/>"/>

SOURCE Vasogen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation
2. Vasogen Announces Third Quarter 2007 Results
3. Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences
4. Vasogen Provides an Update on ACCLAIM-II Preparations
5. Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure
6. Vasogen to Conduct Year-end 2007 Conference Call
7. Vasogen Announces 2007 Year-End Results
8. The Lancet Publishes Vasogens ACCLAIM Results
9. Vasogens Research Published in European Journal of Neuroscience
10. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
11. Avicena Group to Present at Noble Financial Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 2014 The Activated Carbon Manufacturing ... is why IBISWorld updated its original industry research report. ... from an intensified focus on environmental policy. Over the ... standards for power plants and a range of other ... Industry Analyst Sarah Kahn, “a range of downstream industrial ...
(Date:12/17/2014)... Once more, EMAAR has selected ... waste water treatment plant to phase one of BayLaSun, ... Two years ago Bioshaft successfully supplied and operated a ... residential towers with an occupancy of 900 residences. ... gallons per day and was signed on September 16th, ...
(Date:12/17/2014)... -- Vermillion, Inc. (NASDAQ: VRML ), a bio-analytic ... next step in its expanded strategy to rebuild the ... naming of current Chief Operating Officer, Valerie Palmieri ... Chairman of the Board and CEO James LaFrance ... are effective January 1, 2015. "Jim and ...
(Date:12/15/2014)... 2014 METTLER TOLEDO is pleased ... ParticleView V19 with PVM technology , is ... vision and measurement tool continuously captures high-resolution images ... V19 then automatically prepares a report pairing the ... and concentration changes. This compelling blend of high ...
Breaking Biology Technology:Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 2Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4New Real-Time In Situ Probe-Based Video Microscope from METTLER TOLEDO 2
... MBA to Join Genencor,s Senior Management Team, ... of Danisco,A/S, today announced that Dr. Glenn E. ... - Technical Enzymes, effective Oct. 1, 2007. As ... Nedwin will head the,division,s activities in Grain Processing ...
... 1 ISTO Technologies, Inc., a privately,held ... States Patent,Office granted a key patent protecting ... "Method for Chondrocyte Expansion with,Phenotype Retention." ... regeneration and,repair in knee joints and spinal ...
... BERKELEY, Calif., Oct. 1 Berkeley BioSciences, Inc.,co-founded ... of the,Department of Nutritional Sciences at UC Berkeley ... of Health Cancer Research Program at UC,Berkeley, announces ... support,formula exclusively licensed from UC Berkeley.,( http://www.ActivaMune.com/ ). ...
Cached Biology Technology:Genencor Appoints New Executive Vice President - Technical Enzymes 2ISTO Technologies Granted Key Patent for Cartilage Cell Expansion by the United States Patent Office 2Advanced Immune Support Formula Licensed From UC Berkeley Launched 2
(Date:12/10/2014)... SUNNYVALE, California , December 9, 2014 /PRNewswire/ ... Integrate with ITN,s BCARD Platform ... secure, cloud-based enterprise meeting scheduling solutions for business-to-business ... International, the world leader in mobile near-field communication ... solutions.      (Logo: http://photos.prnewswire.com/prnh/20140612/691055) , ...
(Date:12/4/2014)... , Dec. 3, 2014  Crossmatch™, a leading ... that its DigitalPersona ® Pro Enterprise software ... been deployed throughout First Bank branch locations in ... South Carolina and Virginia. First Bank, a ... Southern Pines, North Carolina , selected the ...
(Date:11/21/2014)... According to a new market research report ... Control, Intrusion Detection, Parking Management, Under Vehicle Inspection), End ... - Global Forecasts to 2020", published by MarketsandMarkets, The ... $25 Billion in 2014 and is expected to reach ... 8.69%. Browse 116 market data Tables and ...
Breaking Biology News(10 mins):Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3
... computer scientists have found a cheap, quick and copyright-respecting ... resources. The software, now available in an experimental beta ... interface that works on all the most popular computer ... for researchers in neural science," says Gully A.P.C. Burns, ...
... infection with high levels of the virus associated with ... as 27 times, according to a study published in ... Prevention. , Anthony Gunnell, a medical biostatistician and ... reviewed the medical exams of women with non-invasive cervical ...
... "toggle switch" that enables them to morph into highly ... comfortably in their new surroundings, a new study in ... shift between two alternating states -- travelers and nesters ... or spreads to other parts of the body, said ...
Cached Biology News:Beyond the book: Software automates access to brain atlases 2Beyond the book: Software automates access to brain atlases 3High HPV concentrations combined with smoking significantly raise risks of cervical cancer 2High HPV concentrations combined with smoking significantly raise risks of cervical cancer 3Newly discovered behavior in cancer cells signals dangerous metastasis 2Newly discovered behavior in cancer cells signals dangerous metastasis 3
LAB/Probe Mouse-Rabbit DAB Kit...
Novagen's Calf Liver tRNA is qualified for use in reticulocyte lysates for in vitro translation, and is the same supplement used in the Red Nova Lysate ....
Rat monoclonal [HK5.3] to B7 RP1 (Biotin) ( Abpromise for all tested applications). entrezGeneID: 23308 SwissProtID: O75144...
Rabbit polyclonal to ZFP200 ( Abpromise for all tested applications). Antigen: Synthetic peptide: CGKSFNHKTNLNKHER (Human) Entrez Gene ID: 7752 Swiss Protein ID: P98182...
Biology Products: